Clearance of sup 131 I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody

Journal Article · Thu Feb 01 00:00:00 EST 1990 · Cancer Research; (USA)

OSTI ID:7026058

Stewart, J S; Sivolapenko, G B; Hird, V; Davies, K A; Walport, M; Ritter, M A; Epenetos, A A ^[1]

---

1. Hammersmith Hospital, London (England)

Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other patients receiving i.p.-radiolabeled monoclonal antibody for the first time without exogenous human anti-murine immunoglobulin, and who had no preexisting endogenous human anti-murine immunoglobulin antibody. Patients receiving i.v. human anti-murine immunoglobulin antibody demonstrated a rapid clearance of 131I-labeled monoclonal antibody from their circulation. The (mean) maximum 131I blood content was 11.4% of the injected activity in patients receiving human anti-murine immunoglobulin antibody compared to 23.3% in patients not given human anti-murine immunoglobulin antibody. Intravenous human anti-murine immunoglobulin antibody decreased the radiation dose to bone marrow (from 131I-labeled monoclonal antibody in the vascular compartment) 4-fold. Following the injection of human anti-murine immunoglobulin antibody, 131I-monoclonal/human anti-murine immunoglobulin antibody immune complexes were rapidly transported to the liver. Antibody dehalogenation in the liver was rapid, with 87% of the injected 131I excreted in 5 days. Despite the efficient hepatic uptake of immune complexes, dehalogenation of monoclonal antibody was so rapid that the radiation dose to liver parenchyma from circulating 131I was decreased 4-fold rather than increased. All patients developed endogenous human anti-murine immunoglobulin antibody 2 to 3 weeks after treatment.

• OSTI ID: 7026058
• Journal Information: Cancer Research; (USA), Vol. 50:3; ISSN 0008-5472
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MONOCLONAL ANTIBODIES
BLOOD-PLASMA CLEARANCE
NEOPLASMS
RADIOIMMUNOTHERAPY
OVARIES
BONE MARROW
GLYCOPROTEINS
IMMUNOGLOBULINS
IODINE 131
LIVER
PATIENTS
RADIATION DOSES
ANIMAL TISSUES
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
CLEARANCE
DAYS LIVING RADIOISOTOPES
DIGESTIVE SYSTEM
DISEASES
DOSES
FEMALE GENITALS
GLANDS
GLOBULINS
GONADS
HEMATOPOIETIC SYSTEM
IMMUNOLOGY
IMMUNOTHERAPY
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
MEDICINE
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANIC COMPOUNDS
ORGANS
PROTEINS
RADIOIMMUNOLOGY
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY
TISSUES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)